Suxamethonium Chloride BP

Land: Nieuw-Zeeland

Taal: Engels

Bron: Medsafe (Medicines Safety Authority)

Werkstoffen:

Suxamethonium chloride dihydrate 50 mg/mL;  

Beschikbaar vanaf:

Juno Pharmaceuticals NZ Limited

INN (Algemene Internationale Benaming):

Suxamethonium chloride dihydrate 50 mg/mL

Dosering:

50 mg/mL

farmaceutische vorm:

Solution for injection

Samenstelling:

Active: Suxamethonium chloride dihydrate 50 mg/mL   Excipient: Hydrochloric acid Sodium hydroxide Water for injection

Eenheden in pakket:

Polyamp, 50 x 2ml, 100 mL

klasse:

Prescription

Prescription-type:

Prescription

Geproduceerd door:

Zydus Takeda Healthcare Pvt. Ltd.

therapeutische indicaties:

For the production of skeletal muscle relaxation in anaesthesia. Suited for procedures requiring only brief relaxation such as endotracheal intubation, endoscopic examinations, orthopaedic manipulations, short surgical procedures and electro-convulsive therapy.

Product samenvatting:

Package - Contents - Shelf Life: Polyamp, 2ml - 50 dose units - 15 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)

Autorisatie datum:

1990-07-04

Productkenmerken

S
UXAMETHONIUM
Data Sheet 181017
NEW ZEALAND DATA SHEET
1.
PRODUCT
NAME
S
UXAMETHONIUM
C
HLORIDE
I
NJECTION
B.P. 50 mg/mL
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 2 mL of solution contains 100 mg of suxamethonium chloride BP
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Injection
solution:
a
clear,
colourless,
particle-free
solution
containing
50 mg/mL
suxamethonium chloride.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For the production of skeletal muscle relaxation in anaesthesia.
Suited for procedures
requiring only brief relaxation such as endotracheal intubation,
endoscopic examinations,
orthopaedic manipulations, short surgical procedures and
electro-convulsive therapy.
4.2
DOSE AND METHOD OF ADMINISTRATION
Dosage
is
individualised
and
its
administration
should
be
determined
after
careful
assessment of the patient. The dose of suxamethonium is dependent on
bodyweight, the
degree
of
muscle
relaxation
required
and
the
response
of
individual
patients.
Suxamethonium causes paralysis of the respiratory muscles, therefore
after administration,
respiration must be controlled. It should not be administered to a
conscious patient.
Suxamethonium should not be mixed with any neuromuscular blocking
agent, nor with
general anaesthetics such as short acting barbiturates, nor any other
therapeutic agent in
the same syringe.
Suxamethonium Chloride contains no antimicrobial agent. It should be
used only once and
any residue discarded.
An initial test dose of 0.1 mg/kg may be given intravenously to
determine the patient’s
response.
ADULT
For short procedures, such as endotracheal intubation the usual adult
dose is 0.6 mg/kg
(range 0.3-1.1 mg/kg) administered IV over 10 to 30 seconds. This dose
produces muscle
relaxation in about 60 seconds and has a duration of approximately 4
to 6 minutes. Larger
doses produce more prolonged muscle relaxation.
S
UXAMETHONIUM
Data Sheet 181017
2
For more prolonged surgical procedures in an adult, suxamethonium is
commonly given by
IV
infusion
at
a
r